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Abstract
Introduction: HIV self-testing (HIVST) is being introduced as a new way for more undiagnosed people to know their HIV sta-
tus. As countries start to implement HIVST, assuring the quality and regulating in vitro diagnostics, including HIVST, are essen-
tial. We aimed to document the emerging regulatory landscape and perceptions of key stakeholders involved in HIVST policy
and regulation prior to implementation in three low- and middle-income countries.
Methods: Between April and August 2016, we conducted semi-structured interviews in Malawi, Zambia and Zimbabwe to
understand the relationships between different stakeholders on their perceptions of current and future HIVST regulation and
the potential impact on implementation. We purposively sampled and interviewed 66 national-level key stakeholders from the
Ministry of Health and the regulatory, laboratory, logistical, donor and non-governmental sectors. We used a thematic
approach to analysis with an inductively developed common coding framework to allow inter-country comparison of emerging
themes.
Results: In all countries, the national reference laboratory was monitoring the quality of HIVST kits entering the public sector.
In Malawi, there was no legal mandate to regulate medical devices, in Zambia one regulatory body with a clear mandate had
started developing regulations and in Zimbabwe the mandate to regulate was overlapping between two bodies. Stakeholders
indicated that they had a poor understanding of the process and requirements for HIVST regulation, as well as lack of clarity
and coordination between organizational roles. The need for good collaboration between sectors, a strong post-market surveil-
lance model for HIVST and technical assistance to develop regulators capacity was noted as priorities. Key informants identi-
fied technical working groups as a potential way collaboration could be improved upon to accelerate the regulation of HIVST.
Conclusion: Regulation of in vitro diagnostic devices, including HIVST, is now being recognized as important by regulators
after a regional focus on pharmaceuticals. HIVST is providing an opportunity for each country to develop similar regulations to
others in the region leading to a more coherent regulatory environment for the introduction of new devices.
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1 | INTRODUCTION
The World Health Organization (WHO) defines HIV self-test-
ing (HIVST) as “a process in which a person collects his or her
own specimen (oral fluid or blood) and then performs a test
and interprets the result, often in a private setting, either
alone or with someone he or she trusts” [1]. HIVST has been
put forward as an innovative tool for reaching the remaining
23% (33% to 12%) of people with HIV who do not know their
status [2]. The number of HIVST kits accessible through the
public sector in Africa is increasing rapidly in response to the
global scale-up [3]. The regulation of kits has been identified
as an important emerging area to protect the consumer from
harm [4].
HIVST kits are classed as in vitro diagnostic (IVD), that is tests
on specimens taken from the body, and thus are considered
medical devices by the International Medical Device Regulation
Forum [5]. Medical devices are classified according to the haz-
ard the device presents based on its intended use and the
expertise of the user and the impact of the result. Due to the
potentially severe outcomes of an incorrect result and its use
by lay persons, regulators would likely consider HIVST kits as a
Class D (highest risk) medical device and therefore subject to
the greatest degree of regulation [6]. For an HIVST kit to meet
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the stringent regulatory standards of the International Medical
Device Forum, it must not only demonstrate the stability and
accuracy required for device registration, but also take into
account mechanisms for ensuring the kit performs optimally in
the hands of intended users. HIVST kits approved for use by
regulatory authorities in high-income countries, such as the Uni-
ted States Food and Drug Administration, may take several
years to evaluate and test performance in their specific popula-
tion [7,8]. To speed up this process and make the evaluation
more focused on low- and middle-income countries, in 2016,
the WHO released the technical specifications series for the
pre-qualification (PQ) of HIVST kits [9] and in 2017 the Ora-
Quick® HIV Self-Test was the first device to be given PQ
approval [10].
Surveys of regulation across Africa have identified IVD reg-
ulation as a neglected area [11,12]. In the majority of coun-
tries, including those with generalized HIV epidemics planning
to use the HIVST approach as part of their strategic response,
HIVST remains unregulated [4,12]. Many low- and middle-
income countries and donors use WHO PQ as a pre-requisite
or substitution for device registration. However, PQ does not
cover all monitoring of device performance undertaken once a
device is on the market (post-market surveillance) though an
adverse event reporting system is in place [13]. For profes-
sional use HIV rapid diagnostic tests (RDTs), programmes for
external quality assurance (EQA) have been developed for
resource-limited settings to compare testing performance
between sites [14]. In Africa, EQA programmes are largely run
by the tertiary HIV referral laboratories or national reference
laboratories and act as a post-market surveillance system in
the absence of or, where available, in collaboration with IVD
regulators. These approaches require adaptation to work for
HIVST. However, at present many of these EQA programmes
are not working due to insufficient funding [15].
We set out to determine the current regulatory status of
HIVST in Malawi, Zambia and Zimbabwe and document the
perceptions and suggestions of key stakeholders regarding
current and future HIVST regulation in each country. These
countries had been selected for the Unitaid/PSI HIV Self-Test-
ing in AfRica (STAR) project based on their high HIV preva-
lence (Malawi 9.2%, Zimbabwe 13.5% and Zambia 12.4%),
established community-based HIV testing services, availability
of data from pilot studies on HIVST and importantly, local gov-
ernment support for HIVST [16-19]. The STAR project aims to
catalyse the market for high quality HIVST. Appropriate effec-
tive regulation is required to meet this aim.
2 | METHODS
We used qualitative and policy analysis methods to under-
stand the relationships between different stakeholders, their
perceptions of current and future regulation and its links to
potential scale-up [20,21]. We sought to document the cur-
rent understanding and knowledge of HIVST regulation and
to explore sensitive areas around how the development of
regulation for HIVST can be influenced by context and indi-
vidual stakeholders. Individual semi-structured interviews
with key informants were conducted at the convenience of
the key informants [22]. The consolidated criteria for report-
ing qualitative research were used when preparing this
manuscript to ensure all relevant information was included
[23].
2.1 | Selection of study participants
The study took place in Malawi, Zambia and Zimbabwe. We
considered stakeholders likely to give in-depth information on
regulation in each country and/or who were likely to play a
key role in HIVST scale-up. We developed lists of participants
with input from country research teams using both relevant
policy and regulatory documents and local knowledge. We fur-
ther supplemented this list by snowball sampling.
2.2 | Data collection
We developed topic guides informed by literature on regula-
tion, global and national policies on HIV testing and HIVST
and implementation experience related to HIVST and based
on the policy triangle framework. The policy triangle is a
framework developed to examine not only the content of pol-
icy but also why is it needed (context), the stakeholders
involved (actors), and how it is developed and implemented
(the process). The topic guides focused on questions consid-
ered to be important in HIVST including key informants’ per-
ceptions on the current and future processes for regulation of
HIVST, key stakeholders in regulation and policy and their
relationships and views on the context of scale-up of HIVST in
each country (Data S1). Additional questions were added iter-
atively after interim analysis of emerging themes. Participants
gave written consent to be interviewed. Interviews were con-
ducted in English between April and August 2016, by RD, VW,
LN and CM. Interviews were digitally recorded and emerging
themes discussed within the research team to triangulate find-
ings.
2.3 | Data analysis and trustworthiness
Audio recordings of the interviews were transcribed verbatim
and NVivo qualitative data analysis Software (QSR Interna-
tional Pty Ltd. Version 11, 2017) was used to manage the
data. VW and RD independently coded a subset of ten tran-
scripts each and then met to determine consensus and mini-
mize inter-coder variability for quality control purposes [24].
A thematic approach for data analysis was used which gener-
ated themes inductively based on what emerged from the
data [25]. In order to ensure trustworthiness, initial analysis
was discussed and refined by all the interviewers. Findings
were then presented to a wider audience of researchers, reg-
ulators, WHO staff and policymakers from the three countries
at a STAR consortium meeting in Lusaka in October 2016 and
an international HIVST workshop held in Nairobi in March
2017, with the subsequent feedback and discussion further
informing the analysis [26].
2.4 | Ethical considerations
We obtained ethical approval from the Liverpool School of
Tropical Medicine(Ref: 15.030, University of Zambia (Ref:
013-11-15) and Medical Research Council of Zimbabwe (Ref:
MRCZ/A/180) and the Malawian College of Medicine
Research Ethics Committee (Ref: P.01/16/1860).
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3 | RESULTS
We purposively sampled a total of 66 national-level key infor-
mants across the three countries (Table 1). Three main
themes emerged from the interviews: (1) the limited capacity
for IVD regulation, (2) the need for improved coordination for
IVD regulation, and (3) a desire for international and regional
harmonization. These are summarized in Table 2.
3.1 | Limited capacity for IVD regulation
Across all three countries, knowledge and understanding of
IVD regulation and HIVST was limited. Few key informants
were clear on what regulation for HIVST would entail. Both
Zambia and Zimbabwe medicines regulatory authorities (Zam-
bia Medicines Regulatory Authority (ZAMRA) and The Medici-
nes Control Authority of Zimbabwe (MCAZ), respectively)
reported that they were starting to develop regulations for
IVDs, though not specific to HIVST. While most participants in
Zambia identified ZAMRA as having the mandate for IVDs,
several others thought HIVST regulation would be handled by
the Central Medical Stores or the laboratory technical work-
ing group. A small number of laboratory staff thought other
authorities would need to be involved, such as the Bureau of
Standards.
In Zimbabwe, respondents from two authorities reported
that they considered themselves to be mandated to regulate
HIVST kits (MCAZ and the Medical Laboratory and Clinical
Sciences Council of Zimbabwe (MLCSCZ)). However, at the
time of the interviews neither had started regulating HIVST
kits and it was unclear to respondents who had the regulatory
mandate: “No, actually I have just assumed that they do go
through MCAZ [Medicines Control Authority of Zimbabwe]
but I am not sure. It is very unclear” (Zimbabwe KII23 Male).
The majority of respondents reported it was either the
MLCSCZ or MCAZ with an approximately equal proportion
suggesting it was both. However, some respondents also men-
tioned the need to have regulatory approvals from the Health
Professions Association and the Standards Association of
Zimbabwe.
In Malawi, the majority of policymakers and laboratory staff
identified that there were no regulated HIVST kits in Malawi.
Most identified the national reference laboratory as the
responsible body for regulating IVDs, with a few laboratorians
and NGO staff respondents reporting that they thought Phar-
macy, Medicines and Poisons Board (PMPB) was responsible
for regulating IVDs. While respondents indicated that legal
mandates for IVDs regulations were unclear, they were aware
of a process to provide more clarity, such as the PMPB seek-
ing the mandate to regulate through an Act of Parliament: “In
fact, they [parliament] are reviewing their Act [of Parliament]
at present to include medical devices” (Malawi KII20 Male).
While most identified the national reference laboratory as
responsible for IVDs, the majority of respondents felt that
regulations of professional use, as well as HIVST kits, should
move to the PMPB in the future: “The issue of regulation is
different because the reference laboratory is not a regulator.
The Pharmacy, Medicines and Poisons Board is a regulator.
That is one of their roles” (Malawi KII18 Female).
Regulators in all countries expressed a need for more sup-
port to develop IVD regulations. None of the countries had
regulations that entirely covered the regulation of IVDs or
any specific guidance on HIVST regulation. In Zambia, regula-
tors said they were focusing on getting guidelines developed
for the pre-market registration of products. In Zimbabwe, they
were focusing on import and export regulations. In Malawi,
regulators were focused on product registration, but noted
that they needed support to develop IVD regulations: “Defi-
nitely we have to have the capacity and indeed so in the pro-
cess of our capacity building, we have to actually develop
those skills [in IVD regulation]” (Malawi KII14 Male).
3.2 | The need for improved coordination for IVD
regulation
In all countries, significant potential to support HIVST regula-
tion existed between the Ministry of Health HIV department,
national reference laboratory and the IVD regulator. Key
informants consistently recognized that links between policy-
makers, regulators and laboratorians were weak: “I think the
link is quite weak, we don’t really have much interaction”
(Malawi KII12 Male). Some regulatory key informants in Zim-
babwe and Malawi reflected that greater collaboration maybe
useful considering that medical devices were new: “Medical
devices would be a new thing, that’s why probably we are
doing the regulations. Perhaps then we cannot be exclusive”
(Zimbabwe KII10 Female).
The lack of an effective regulation system and of a coordi-
nated approach was a concern for all respondents in all coun-
tries. A key concern was the potential entry of unregulated
and poor quality HIVST kits into the domestic market and was
regarded as a risk for all countries. All key informants in
Malawi and Zambia indicated that they had not seen HIVST in
the private sector. However, in Zimbabwe the majority of poli-
cymakers thought that HIVST was available in the private sec-
tor, indicating that regulation was urgently required: “We hear
people are already selling, kits are out there” (Zimbabwe
KII21 Female).
The quality of HIVST kits, particularly their performance in
the hands of intended users, was a concern for the majority
of key informants across all countries as illustrated by a
respondent from Zambia: “If somebody has a false negative, it
could be a real issue because they suddenly don’t think they
Table 1. Key informant characteristics
Participant constituency
Number of participants
interviewed
Malawi Zambia Zimbabwe
Ministry of Health Policymaker 6 3 4
Regulator 3 1 4
Laboratory 4 3 2
Pharmacy/stores 1 1 3
NGOs 3 6 7
WHO/UN 2 2 4
Donors 4 0 3
Total 23 16 27
WHO, World Health Organization.
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have HIV” (Zambia KII4 Male). There was concern from the
majority of key informants around the type of post-market
surveillance model to be used for HIVST as it would not be
performed by professionals in facilities. The majority of labora-
torians and policymakers across countries were concerned
with how to monitor false non-reactive results: “Most likely
we will see the positives in the test facility. [The concern is]
The ones who come out with a negative and they don’t come
to the facility” (Zambia KII17 Female).
Technical working groups with a mandate to focus on
HIVST were seen as a way of coordinating the development
of policy and regulation. In Malawi, most key informants felt
the scale-up of HIVST should be coordinated by the HIV
Testing and Counselling Technical Working Sub-group and a
minority of laboratorians thought it should be coordinated
through the laboratory technical working group. Notably, nei-
ther group included PMPB. They instead belonged to a differ-
ent technical working group: “At the moment we are in what
is called drug and medical supplies [technical working group]”
(Malawi KII14 Male).
In Zambia, there was no regulatory involvement in the HIV
counselling and testing technical working groups though one
policymaker indicated that ZAMRA initiated some ad hoc
meetings with the Ministry of Health. Some policymakers indi-
cated that approval by the national reference laboratory
would be part of HIVST regulation but the ZAMRA were con-
sidering outsourcing to a different laboratory: “The best out-
sourced reference lab that I might point out is the Bureau of
Standards” (Zambia KII6 Female).
Memoranda of understanding were identified as a possible
mechanism by which different organizations could work
together. However, regulatory key informants in Zimbabwe
thought split mandates needed to be addressed in a way that
the mandate rests with one regulator only: “How we team up
with them is through MOUs” (Zimbabwe KII10 Female). “So,
let’s work together you as medicine laboratory scientists,
Table 2. Main themes emerging from interviews
Theme Country Category Supporting Quote Source
Limited capacity for
IVD regulation
Malawi No authority with legal
mandate for IVD regulation
“In fact, they [parliament] are reviewing their
Act [of Parliament] at present to include
medical devices”
Malawi KII20
Zimbabwe Two authorities considered
mandated to regulate IVDs
“No, actually I have just assumed that they
do go through MCAZ [Medicines Control
Authority of Zimbabwe] but I am not sure.
It is very unclear”
Zimbabwe KII23
All Support required to develop
regulations
“Definitely we have to have the capacity and
indeed so in the process of our capacity
building, we have to actually develop those
skills [in IVD regulation]”
Malawi KII14
The need for improved
coordination for IVD
regulation
All Weak coordination between
ministries of health,
regulators and national
reference laboratories
“I think the link is quite weak, we don’t really
have much interaction”
Malawi KII12
Zimbabwe
and Malawi
Need for greater collaboration
by regulator
“Medical devices would be a new thing,
that’s why probably we are doing the
regulations. Perhaps then we cannot be
exclusive”
Zimbabwe KII 10
All Regulator not part of HIV self-
testing technical working
groups/task forces
“At the moment we are in what is called
drug and medical supplies [technical
working group]”
Malawi KII14
International and
regional
harmonization
All WHO pre-qualification an
important mechanism for
ensuring the quality of test
kits
“For now, we are happy to look at what
WHO has recommended as a bare
minimum, then we will add additional
prerequisites ourselves, but it must have a
recommendation from WHO. If they are
fully pre-qualified that’s even better”
Zambia KII12
All Coordination between
countries seen as benefit for
developing regulations
“It’s a matter of trying to get Malawi at the
table to see how other countries are
doing so they can set up something
similar”
Malawi KII13
IVD, in vitro diagnostic.
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evaluating controlling regulating kits for us but not the other
way around” (Zimbabwe KII27 Female).
3.3 | International and regional harmonization
WHO pre-qualification was recognized by key informants from
all sectors, across all countries, as an important mechanism
for ensuring the quality of test kits from manufacturers. Most
also stated that it was a procurement requirement from
donors as illustrated by this commonly held view: “For now,
we are happy to look at what WHO has recommended as a
bare minimum, then we will add additional prerequisites our-
selves, but it must have a recommendation from WHO. If they
are fully pre-qualified that’s even better” (Zambia KII12
Female).
There was little mention of the existence of any regional
bodies or other inter-country interactions other than with
the WHO for IVD regulation, but participants from all sec-
tors were aware of the benefits of a shared approach and
were open to the possibility. One regulatory key informant
indicated they were using other countries’ regulations to
base their own draft IVD regulations on: “you see, we pick it
up from different countries and then we sort of custom
make our own” (Zimbabwe KII10 Female). Similarly, ZAMRA
were reported to be looking at regional collaboration: “We
will sit down as regulators and say fine how are we going to
look at this because I know Zimbabwe had some guidelines”
(Zambia KII6 Female). Recognition of regional efforts for col-
laboration was also seen amongst laboratorians and regula-
tors as indicated by this key informant: “It’s a matter of
trying to get Malawi at the table to see how other countries
are doing so they can set up something similar” (Malawi
KII13 Male).
4 | DISCUSSION
HIVST is a relatively new technology, especially in the context
of regulations in low- and middle-income countries [27]. Our
research found that the development of regulation for IVDs
ranged from none in one country to the drafting of guidelines
for pre-market regulation in the other two countries. We
found lack of clarity of roles and responsibilities across differ-
ent organizations and regulatory authorities making it difficult
to determine who was responsible for HIVST regulations in
country. We also found that overlapping mandates for regulat-
ing in vitro diagnostics may be a significant factor in delaying
the development of regulations and could result in stalemate
or the development of conflicting regulations. Key informants
we interviewed were particularly concerned about the perfor-
mance of HIVST in the hands of intended users and the impli-
cations for post-market surveillance despite evidence to the
contrary [28].
The potential role of HIV National Reference Laboratories
who are already monitoring HIV kits for professional use, in
post-market surveillance of HIVST had not been recognized
by most regulators. There is a clear, recognized need for
strengthened regulatory capacity for medical device regula-
tors, HIV departments and National Reference Laboratories
and clarity on their roles in HIVST regulation, so policy and
regulation can be properly aligned and the experience of
reference laboratories in checking HIV kits can be properly
utilized.
HIVST regulation and implementation is a rapidly evolving
field. A study conducted in 2013 involving similar constituents,
and in the case of Malawi some of the same individuals,
showed that few participants had come across HIVST in prac-
tice [29]. Concerns were voiced about the need for coun-
selling and the potential for coercive testing and to a lesser
extent about kit accuracy. In contrast, we found widespread
familiarity with HIVST as an approach and more focus on con-
cerns over test performance and systems for quality assur-
ance. The development of post-market surveillance systems
able to detect false non-reactive results is of concern in other
studies too [29,30] but we are not aware of any programmes
that have successfully addressed this. Current HIV quality
assurance approaches are designed for facility-based rapid
testing, where testing is conducted by trained testers who
record results and where kit storage and lot numbers can be
traced [31]. Alternative approaches to monitoring HIVST per-
formance, such as the visual stability of kits for re-reading,
digital photography and direct observation need further inves-
tigation [32,33].
HIVST regulation has failed to keep pace with the scale-up
of HIVST and IVD regulation in general and is underdeveloped
in many countries [11,12]. Globally, only one HIVST device
has been pre-qualified by the WHO and the process to gather
the evidence required for dossier submission can take many
years [34]. Our findings of poor national-level coordination
and capacity have implications for both manufacturers trying
to enter these local markets and for end users. For manufac-
turers, the fragmented and uncertain regulatory environment
creates barriers that mean they are reluctant to take the
financial risks associated with the development of high quality
HIVST products. Manufacturers lack incentives to innovate
further product development and prices for existing products
remain high due to lack of competition [35]. For end users,
the delays could result in the proliferation and use of unregu-
lated low quality tests and ultimately incorrect HIV screening
results and loss of consumer confidence [36].
The current lack of IVD regulation in many African coun-
tries presents an opportunity for regulatory convergence
between countries. Regional groups, such as the Pan African
Harmonization Working Party [37] and the African Society for
Laboratory Medicine [38], already exist with this aim but lack
adequate resourcing and political prioritization. Regional coor-
dination can develop capacity, save time and effort and speed
up costly, cumbersome and duplicative processes. Four key
areas to aid convergence are: common pre-market registra-
tion; joint manufacturing site inspections; joint data review
and evaluation protocols and the establishment of laboratory
networks for post-market surveillance [12,39]. Our findings
indicate WHO pre-qualification is likely to be an important
component of any common pre-market HIVST registration sys-
tem in the African region provided manufactures buy into the
process [40]. Collaborative regulatory procedures (e.g. reviews
of dossier submissions) make a more attractive regulatory
environment for manufacturers who would no longer need to
submit different dossiers to multiple regulatory authorities
[41].
National leadership links HIVST to the wider HIV testing
strategy and brings key stakeholders under a common vision.
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A single coordinated approach that establishes roles and
responsibilities from an early stage, will allow a complete pic-
ture of HIVST situation within the country, linking HIV testing
policymakers, regulators and laboratory stakeholders. Experi-
ence from policy development elsewhere reveals that power,
inclusive of funders, politics and patronage can play as much
of a role in delaying or pushing through policy as evidence
and need [42]. The current fragmented approach risks exacer-
bating this situation when there is a lack of direction, conver-
gence within intra-country constituencies and strong
leadership.
The study shares limitations of qualitative approaches in
general, principally the non-generalizability of study findings.
However, the qualitative approach insisting on depth rather
than breadth was suitable for our study since it enabled us to
explore, describe and analyse sensitive issues related to a new
testing approach. Though we interviewed a wide range of par-
ticipants across seven different sectors, the small number of
respondents in some categories made comparison across
groups difficult. Due to a limited number of possible respon-
dents, countries rather than constituencies have been used
for attribution of illustrative quotations to protect individual’s
anonymity. Some areas related to regulation such as govern-
ment procurement processes and supply chain were not
explored in depth during the interviews to try and focus more
on the barriers and opportunities to developing regulations.
5 | CONCLUSIONS
The recognition of the role of regulation in the scale-up of
HIVST is important to ensure the market only has high quality
test kits that can be used correctly and confidently by
intended users. Programmes should establish clear lines of
communication with IVD regulators early to allow for the
alignment of policy and regulation and ensure all voices are
heard in their respective development. The expertise of HIV
National Reference Laboratories should be used to assist in
the evaluation of HIVST kits and the development of post-
market surveillance systems.
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